UC San Diego Health Sciences schools, institutes and centers are at the forefront of discovery and transformation.
The U.S. National Science Foundation announced $30 million in research awards to support new interdisciplinary, fundamental research projects for the Emerging Frontiers in Research and Innovation (EFRI) program — 20 percent of the funding was awarded to UC San Diego researchers.
Researchers at UC San Diego report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer, which kills more than 34,000 men in the U.S. annually.
UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.
One in every eight strokes at UC San Diego Health occur in an adult younger than 50.
In animal models, UC San Diego researchers found that intensive physical therapy in tandem with implanted neural stem cells increased tissue growth, repair and functionality in spinal cord injuries more than those treatments alone.
UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.
Forbes, May 29
San Diego Union Tribune, May 28
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
